帕诺:一种用于透析患者的新型治疗剂,患有高酸血症
Tadao Akizawa1, Natsuki Urano2, Kazuaki Ikejiri2
1Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
概括
帕诺尔为透析患者的高血症提供了一种新的治疗方法,有效降低水平. 它还降低了药丸负担,改善了患者的坚持和结果.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 过血是透析患者常见的并发症,增加心血管风险和死亡率.
- 现有的酸盐结合剂 (PBs) 有局限性,包括副作用和高药剂负担,妨碍有效的控制.
- 特纳帕诺是一种新型选择性/质子交换载体3抑制剂,于2023年在日本批准用于高酸血症.
研究的目的:
- 审查特征和临床研究的tenapanor治疗高酸血症.
- 评估tenapanor作为单疗法和附加疗法的疗效和安全性.
- 评估tenapanor在减轻透析患者药物负担方面的潜力.
主要方法:
- 在日本进行的四项第三阶段临床研究的综述.
- 在控制血清含量方面分析tenapanor的有效性.
- 对特纳帕诺尔的安全性概况和对药丸负担的影响的评估.
主要成果:
- 帕诺尔作为单剂治疗高酸血症的疗效被证明是有效的.
- 添加治疗与tenapanor改善了对PB单独耐药的患者的控制.
- 帕诺的使用与减少酸盐结合剂的药片负担有关.
结论:
- 帕诺为透析患者管理高酸血症提供了一种新的治疗选择.
- 它作为单一疗法或附加剂的双重作用为治疗策略提供了灵活性.
- 与传统的PB相比,Tenapanor可以通过减少药物负担来改善患者的坚持和结果.
相关概念视频
01:28Antihypertensive Drugs: Potassium-Sparing Diuretics
443
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
443
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
378
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
129
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
129
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
147
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
147
01:25Antihypertensive Drugs: Direct Renin Inhibitors
482
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
482
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
132
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
132